Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non-agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.

Abstract: A polypeptide comprising a crystallizable fragment (Fe) region of IgG for use in prevention or treatment of a disease, in particular of a disease affecting the central nervous system. The polypeptide is administered locally to compartments, in particular to the central nervous system. The Fe region comprises the mutations I253N and H435Q and an H at position 310 resulting in reduced affinity to the neonatal Fe receptor (FeRn), resulting in an increased brain to serum concentration of the polypeptide.

Abstract: A polypeptide comprising a crystallizable fragment (Fc) region of IgG for use in prevention or treatment of a disease, particularly a disease affecting the central nervous system. The polypeptide is administered locally to the affected compartment, in particular to the central nervous system. The Fc region bears a modification resulting in reduced affinity to the neonatal Fc receptor (FcRn), resulting in an increased brain to serum concentration of the polypeptide.

Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non -agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.

Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.